Nina A. Karaseva

机构：City Clinical Oncology Center

发表论文 44 篇 · 总被引 9219 次 · h-index 23

代表论文

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019 · The Lancet · 被引 3385)
• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer (2020 · JAMA Oncology · 被引 1167)
• Perioperative Nivolumab in Resectable Lung Cancer (2024 · New England Journal of Medicine · 被引 515)
• Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study (2023 · The Lancet Oncology · 被引 377)
• Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial (2019 · The Lancet Oncology · 被引 288)
• Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial (2020 · Annals of Oncology · 被引 198)